PMID- 10377350
OWN - NLM
STAT- MEDLINE
DCOM- 19990715
LR  - 20231104
IS  - 0270-6474 (Print)
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Linking)
VI  - 19
IP  - 13
DP  - 1999 Jul 1
TI  - Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons 
      requires neurotrophins in vivo and in vitro.
PG  - 5409-19
AB  - The medium spiny neuron (MSN) is the major output neuron of the caudate nucleus 
      and uses GABA as its primary neurotransmitter. A majority of MSNs coexpress 
      DARPP-32 and ARPP-21, two dopamine and cyclic AMP-regulated phosphoproteins, and 
      most of the matrix neurons express calbindin. DARPP-32 is the most commonly used 
      MSN marker, but previous attempts to express this gene in vitro have failed. In 
      this study we found that DARPP-32 is expressed in <12% of E13- or E17-derived 
      striatal neurons when they are grown in defined media at high or low density in 
      serum, dopamine, or Neurobasal/N2 (Life Technologies), and ARPP-21 is expressed 
      in <1%. The percentage increases to 25% for DARPP-32 and 10% for ARPP-21 when the 
      same cells are grown in Neurobasal/B27 (Life Technologies) for 7 d. After growth 
      in Neurobasal/B27 plus brain-derived neurotrophic factor (BDNF) for 7 d, 
      E13-derived MSNs are 53.7% DARPP-32-positive and 29. 0% ARPP-21-positive; 
      E17-derived MSNs are 66.8% DARPP-32-positive and 51.5% ARPP-21-positive. The 
      percentage of calbindin-positive neurons also is increased under these 
      conditions. Finally, ARPP-21 expression is reduced in mice with a targeted 
      deletion of the BDNF gene. We conclude that BDNF is required for the maturation 
      of a large subset of patch and matrix MSNs in vivo and in vitro. In addition, we 
      introduce a culture system in which highly differentiated MSNs may be generated, 
      maintained, and studied.
FAU - Ivkovic, S
AU  - Ivkovic S
AD  - The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, 
      USA.
FAU - Ehrlich, M E
AU  - Ehrlich ME
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Calbindins)
RN  - 0 (Culture Media)
RN  - 0 (Dopamine and cAMP-Regulated Phosphoprotein 32)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (S100 Calcium Binding Protein G)
RN  - 125004-22-0 (cyclic AMP-regulated phosphoprotein ARPP-21)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/genetics/*pharmacology/physiology
MH  - Calbindins
MH  - Caudate Nucleus/*cytology
MH  - Cell Count/drug effects
MH  - Cell Culture Techniques/methods
MH  - Cell Differentiation/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Culture Media
MH  - Dopamine/pharmacology
MH  - Dopamine and cAMP-Regulated Phosphoprotein 32
MH  - Female
MH  - Gene Deletion
MH  - Gene Expression Regulation/*drug effects
MH  - Mice
MH  - Nerve Growth Factors/pharmacology
MH  - Nerve Tissue Proteins/*metabolism
MH  - Neurons/cytology/drug effects/*metabolism
MH  - Phosphoproteins/*metabolism
MH  - S100 Calcium Binding Protein G/metabolism
MH  - gamma-Aminobutyric Acid/*physiology
PMC - PMC6782303
EDAT- 1999/06/23 00:00
MHDA- 1999/06/23 00:01
PMCR- 2000/01/01
CRDT- 1999/06/23 00:00
PHST- 1999/06/23 00:00 [pubmed]
PHST- 1999/06/23 00:01 [medline]
PHST- 1999/06/23 00:00 [entrez]
PHST- 2000/01/01 00:00 [pmc-release]
AID - 3170 [pii]
AID - 10.1523/JNEUROSCI.19-13-05409.1999 [doi]
PST - ppublish
SO  - J Neurosci. 1999 Jul 1;19(13):5409-19. doi: 10.1523/JNEUROSCI.19-13-05409.1999.